Gross-To-Net FOMO:
What GTN Dangers Are You Missing Post-Launch?
Your on-demand access to the recorded discussion is now available.
Uncover the Hidden GTN Risks Impacting Your Bottom Line
What You Don't Know About GTN Pressures Could Be Costing You Millions
Gross-to-net (GTN) planning doesn’t end at launch—it evolves. While pre-launch strategies account for rebates, distribution fees, and payer contracts, the real challenges emerge post-launch. Incognito accumulators & maximizers, pharmacy economics, and unexpected claim behaviors can quietly erode your program dollars, leaving you accountable for losses you couldn’t predict.
In this webinar, we’ll explore:
- The evolving dynamics of GTN pressures post-launch
- How accumulators, maximizers, and pharmacy economics impact your copay funds
- Strategies to identify and mitigate risks before they affect your bottom line
Featuring a Conversation with:
.png?width=240&height=240&name=Dowd%20-%20Chris%202023%20(2).png)
.png?width=320&height=320&name=Dowd%20-%20Chris%202023%20(2).png)
SVP, Market Development, ConnectiveRx
In his more than 25-year career, Chris has become a recognized voice in the patient affordability and specialty medication arena, pioneering prominent copay and patient affordability programs, and creating innovative solutions for his clients.
A recognized leader in the space, Dowd has been on the forefront of virtually every development in the patient copay industry over the past decade.
Chris leads strategic market analysis and product go-to-market strategies at ConnectiveRx.
Founder, NextGen GTN™
Dan joins the conversation with over 30 years of industry experience, focusing mainly on commercial biologic products, with expertise on both the medical and pharmacy sides.
He is currently the Executive Director of Access Services and Reimbursement at Regeneron, leading the access services and field reimbursement team, which includes all HUBs and field reimbursement teams across the portfolio.
In the past, he's also served in similar roles at top pharma organizations such as Fujisawa (Astellas), MedImmune (AZ), and Auxilium (Endo).
Industry Smarts
Check out the latest from our team of industry veterans and service innovators here at ConnectiveRx.
- Awareness and Adherence
Pharma Messaging 2025: What's Hot, What's Next, and Why It Matters
Read MoreAre Your Patient Support Programs IRA Ready?
Hub and copay programs are likely to encounter complex payer tactics like benefit redesign and reduced plan availability. Our recent live event offers expert insights on navigating these challenges effectively.
